Lead sponsor
Shanghai Minwei Biotechnology Co., Ltd
12 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of November 5, 2026.
12
Trials led
6
Ongoing
2,051
Total enrollment
7
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
6
Phase 2
5
Phase 3
1
Trials by status
Not yet recruiting
1
Recruiting
3
Active, not recruiting
2
Completed
6
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Phase 3 Study of MWN109 Injection in Participants With Overweight or ObesityBMI ≥28Ph 3Not yet recruiting760
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes MellitusBMI ≥20Ph 2Recruiting240
A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese ParticipantsBMI ≤30Ph 1Completed162
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With OverweightBMI ≥30Ph 2Active, not recruiting125
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or ObesityBMI ≥30Ph 2Completed120
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or ObesityBMI ≥18.5Ph 2Active, not recruiting71
Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or ObesityBMI 27-35Ph 1Completed40